相关实验视频
Updated: Jul 9, 2025
08:39
Establishment of Deep Hypothermic Circulatory Arrest in Rats
Published on: December 16, 2022
2.3K
急性pyrifos中毒对正常血压和高血压大鼠的生存和心肺功能有不同的影响
Andrew Vieira Aitken1, Vítor Sampaio Minassa2, Thatiany Jardim Batista3
1Postgraduate Program in Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Federal University of Espírito Santo, Vitória, ES, Brazil; Department of Anatomy, Physiology, and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, USA.
Chemico-biological interactions
|December 2, 2023
概括
急性有机 (OP) 中毒,就像pyrifos (CPF),对高血压患者来说更危险. 高血压增加了对OP毒性病的易感性,导致严重的心血管和呼吸系统问题.
科学领域:
- 毒理学 毒理学 毒理学
- 心血管生理学心血管生理学
- 神经科学是一个神经科学.
背景情况:
- 高血压是一个主要的心血管疾病 (CVD) 风险因素.
- 急性有机中毒 (OP) 越来越多地被认为是心血管疾病的危险因素.
- 没有研究直接比较了高血压和正常血压状态中的OP中毒效应.
研究的目的:
- 在正常血压和自发高血压大鼠 (SHR) 中调查pyrifos (CPF) 中毒的急性毒性和心血管影响.
- 在Wistar和SHR模型中比较CPF对心肺呼吸反射,自主性音调和生物化学标记物的影响.
主要方法:
- 成年雄性Wistar和SHR老鼠被注射了盐水或CPF.
- 监测有毒症迹象,生存率,血压,心率和通风.
- 评估了贝佐尔德-贾里斯克反射 (BJR),化学反射 (CR) 和心脏自主声调 (AUT).
- 测量了胆酶活动,氧化应激标志物和脑干基因表达.
主要成果:
- 与Wistar大鼠相比,CPF在SHR中诱导的毒性显著更高,死亡率为33%.
- 在两种菌株中,CPF在SHR中的通风受损,心肺呼吸反射受影响 (BJR,CR).
- 在Wistar大鼠中,CPF抑制胆酶,增加氧化应激 (AOPP) 和改变脑干炎症标志物 (TNFα,ACE-1).
- SHR表现出降低了Butyrylcholinesterase (BuChE) 活性,这是一个关键的生物储存器.
结论:
- 高血压加剧了急性OP (CPF) 毒性,增加了致死率和严重程度.
- 在CPF中毒后心肺呼吸系统功能障碍与胆固醇干扰,氧化应激和炎症有关.
- 患有高血压的人可能面临急性OP中毒的风险增加.
相关概念视频
01:26Anticholinesterase Agents: Poisoning and Treatment
877
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
877
01:30Acute Respiratory Failure-III
187
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
187
01:21Acute Respiratory Failure-I
213
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
213
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:21Acute Respiratory Failure-II
241
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
241